Sarda Proteins Limited will hold a board meeting on September 7, 2026, at its corporate office. The agenda focuses on approving the Annual General Meeting (AGM) logistics and related compliance matters.

The company notified the BSE Limited under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting aims to finalize key procedural aspects for the upcoming AGM.

Agenda Items

The Board of Directors will transact the following business:

• Approve the date, time, and venue or mode of the AGM.
• Approve the notice convening the AGM and authorize its dispatch to members.
• Fix dates for closing the Register of Members and Share Transfer Books.
• Appoint a scrutinizer for remote e-voting and e-voting processes.
• Transact any other business with the Chair's permission.

Shirish Dhirajlal Savaliya, Managing Director, signed the intimation letter addressed to the General Manager of BSE Limited in Mumbai.

Sarda Proteins Limited approved a rights issue of equity shares amounting to up to ₹1,000 crore during its Board of Directors meeting held on August 5, 2026. The move allows existing shareholders to purchase additional fully paid-up equity shares with a face value of ₹10 each. This capital raise represents a significant financing step for the meat processing company, aiming to strengthen its balance sheet or fund expansion plans, though specific utilization details were not disclosed in the filing. Shareholders must wait for the record date notification to determine eligibility.

The Board approved the issuance in accordance with the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Concurrently, the directors authorized the filing of the Draft Letter of Offer (DLOF) with the Securities and Exchange Board of India (SEBI) and relevant stock exchanges. Procedural compliance was maintained under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To oversee the execution of the capital raise, the Board constituted a Rights Issue Committee. This committee is tasked with managing all matters related to the proposed issue under applicable laws. The committee comprises three key directors from the company’s leadership team.

In a separate development during the same meeting, the Board noted the resignation of non-executive director Gunvantray Jayantilal Zaladi. His resignation takes effect from the close of business hours on August 5, 2026. In his resignation letter dated August 5, 2026, Mr. Zaladi cited personal reasons and pre-occupations as the cause for stepping down. He confirmed there were no material reasons for his departure other than those stated.

The company will separately intimate the record date for the rights issue once finalized, as required under Regulation 42 of the SEBI Listing Regulations. Investors are advised to monitor official communications from Sarda Proteins Limited for further updates regarding the timeline and application process for the rights issue.